… with EGFR wild type NSCLC and multiple brain metastases [15]. Considering that EGFR
TKIs are most active in EGFR mutant NSCLC, it is possible that the synergistic effect between …

… metastasis (BM) in EGFR mutated NSCLC patients. However, whether the combination of
EGFR-TKIs and brain RT is better than EGFR-TKIs … of adding brain RT to EGFR-TKIs and to …

… brain metastases and upfront epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)…
patients treated with upfront local therapy for brain metastases and upfront EGFR-TKI. …

… metastases remains controversial. Thus, we performed a pooled analysis of published …
EGFR-TKIs in NSCLC patients with brain metastases, particularly for tumors with activating EGFR …

… of EGFR-TKI in brain metastases from NSCLC in recent years. Nonetheless, brain metastases
were … clinical studies involving EGFR-TKI and accounts of its use in intracranial lesions are …

… on the incidence of brain metastases has been explored in several … EGFR mutation or
EGFR-TKI use and brain metastases remains to be determined since the sample size of EGFR …

… Also, EGFR mutation positive patients with BM tend to do significantly better as compared to
… type EGFR, when treated with EGFR tyrosine kinase inhibitors (TKIs) and brain irradiation […

… , which would increase the cerebral concentration of TKIs, we performed … EGFR TKI and
WBRT 14. WBRT could increase the penetration of EGFR TKI via disturbing BBB and EGFR TKI …

… metastases.19, 20, 21 Nevertheless, in a large, retrospective study of patients with EGFR-…
shorter in patients receiving EGFR TKI therapy alone versus TKI therapy plus upfront WBRT …

… EGFR (8%) or WT (4%) EGFR TKI use was associated with … patients with brain metastases
harboring either EGFR and … was found with regards to intracranial PFS. The results of our …